DOCSLIB.ORG

(10) Patent N0.: US 8759307 B2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(10) Patent N0.: US 8759307 B2 USOO8759307B2 (12) United States Patent (10) Patent N0.: US 8,759,307 B2 Stein et al. (45) Date of Patent: Jun. 24, 2014 (54) OLIGONUCLEOTIDE COMPOUND AND 2006/0287268 A1 12/2006 Iversen et al. ................. .. 514/44 METHOD FOR TREATING NIDOVIRUS 2007/0021362 A1 1/2007 Geller et al. .. 514/44 INFECTIONS 2007/0265214 A1 ll/2007 Stein et al. 514/44 2009/0088562 A1 4/2009 Weller et al. ............... .. 536/24.5 (75) Inventors: David A. Stein, Corvallis, OR (US); FOREIGN PATENT DOCUMENTS Richard K. Bestwick, Corvallis, OR (US); Patrick L. Iversen, Corvallis, OR WO WO2005/000234 A1 1/2005 (US); Benjamin Neuman, Encinitas, CA WO WO2005/013905 A1 2/2005 (US); Michael Buchmeier, Encinitas, OTHER PUBLICATIONS CA (US); Dwight D. Weller, Corvallis, OR (US) Moulton et al Bioconjug Chem. Mar. -Apr. 2004;15(2):290-9. Cellu lar uptake ofantisense morpholino oligomers conjugated to arginine (73) Assignees: Sarepta Therapeutics, Inc., Corvallis, rich peptides.* OR (US); The Scripps Research Moulton et al Antisense Nucleic Acid Drug Dev. Feb. 2003;13(1):31 Institute, La Jolla, CA (US) 43. HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers.* Notice: Subject to any disclaimer, the term of this Geller et al., Inhibition of Gene Expression in Escherichia coli by patent is extended or adjusted under 35 Antisense Phosphorodiamidate Morpholino Oligomers Antimicro U.S.C. 154(b) by 1101 days. bial Agents and Chemotherapy, Oct. 2003, p. 3233-3239, vol. 47, N0. 10.* Appl. No.: 12/109,856 Agrawal, S., S. H. Mayrand, et al. (1990). “Site-speci?c excision (21) from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides.” Pr0c Nat/Acad Sci USA, 87(4): 1401-5. (22) Filed: Apr. 25, 2008 Agrawal et al., “Antisense therapeutics: is it as simple as complemen tary base recognition?”, Molecular Med. Today, 6:72-81 (2000). (65) Prior Publication Data Allende, R., T. L. Lewis, et al. (1999). “North American and Euro US 2009/0012280 A1 Jan. 8, 2009 pean porcine reproductive and respiratory syndrome viruses differ in non-structural protein coding regions.”JGen ViroL, 80( Pt 2):307-15. Bailey, C. P., J. M. Dagle et al., (1998). “Cationic oligonucleotides Related US. Application Data can mediate speci?c inhibition of gene expression in Xenopus oocytes.” Nucleic Acids Res, 26(21):4860-7. (60) Division of application No. 11/432,155, ?led on May Barawkar, D. A. and T. C. Bruice, (1998). “Synthesis, biophysical 10, 2006, now abandoned, which is a properties, and nuclease resistance properties of mixed backbone continuation-in-part of application No. 11/022,358, oligodeoxynucleotides containing cationic internucleoside ?led on Dec. 22, 2004, now abandoned. guanidinium linkages: deoxynucleic guanidine/DNA chimeras.” Provisional application No. 60/532,701, ?led on Dec. Pr0c NatAcad Sci USA, 95(19): 1 1047-52. (60) Blommers, M. J., U. Pieles, et al. (1994). “An approach to the struc 24, 2003. ture determination of nucleic acid analogues hybridized to RNA. NMR studies of a duplex between 2‘-OMe RNA and an (51) Int. Cl. oligonucleotide containing a single amide backbone modi?cation.” A61K 48/00 (2006.01) Nucleic Acids Res, 22(20):4187-94. C07H 21/04 (2006.01) Bonham, M. A., S. Brown, et al. (1995). “An assessment of the C07H 21/02 (2006.01) antisense properties of RNase H-competent and steric-blocking C12N 7/00 (2006.01) oligomers.” Nucleic Acids Res. 23(7): 1197-203. US. Cl. Boudvillain, M., M. Guerin, et al. (1997). “Transplatin-modi?ed (52) olig0(2‘-O-methyl ribonucleotide)s: a new tool for selective modula USPC .......................... .. 514/44; 536/23.1; 536/24.5 tion of gene expression.” Biochemistry, 36(10): 2925-31. (58) Field of Classi?cation Search CPC ..................................................... .. C12N 15/11 (Continued) USPC ...................... .. 514/44; 536/23.1, 24.5, 235.1 See application ?le for complete search history. Primary Examiner * Maria Leavitt (74) Attorney, Agent, or Firm * Seed IP Law Group PLLC (56) References Cited (57) ABSTRACT U.S. PATENT DOCUMENTS A method and oligonucleotide compound for inhibiting rep 5,185,444 A 2/1993 Summerton et al. lication of a nidovirus in virus-infected animal cells are dis 5,892,023 A * 4/1999 Pirotzky et al. ............ .. 536/24.5 closed. The compound (i) has a nuclease-resistant backbone, 6,365,351 B1 4/2002 Iversen (ii) is capable of uptake by the infected cells, (iii) contains 6,677,153 B2 1/2004 Iversen between 8-25 nucleotide bases, and (iv) has a sequence 6,784,291 B2 8/2004 Iversen et al. 6,828,105 B2 12/2004 Stein et al. capable of disrupting base pairing between the transcriptional 6,841,542 B2 1/2005 BartelmeZ et al. regulatory sequences in the 5' leader region of the positive 7,049,431 B2 5/2006 Iversen et al. strand viral genome and negative-strand 3' subgenomic 7,094,765 B1 8/2006 Iversen et al. region. In practicing the method, infected cells are exposed to 7,468,418 B2 * 12/2008 Iversen et al. 530/300 the compound in an amount effective to inhibit viral replica 7,943,762 B2 5/2011 Weller et al. .................. .. 536/31 2003/0224353 A1 12/2003 Stein et al. tion. 2006/0257852 A1 11/2006 Rappuoli et al. 2006/0269911 A1 11/2006 Iversen et al. ................... .. 435/5 8 Claims, 11 Drawing Sheets US 8,759,307 B2 Page 2 (56) References Cited Moulton, H. M. and J. D. Moulton (2003). “Peptide-assisted delivery of steric-blocking antisense oligomers.” Curr Opin M0l Ther., OTHER PUBLICATIONS 5(2):123-32. Neuman et al., (2004). “Antisense morpholino-oligomers directed Dagle, J. M., J. L. Littig, et al. (2000). “Targeted elimination of against the 5‘ end of the genome inhibit coronavirus proliferation and zygotic messages in Xenopus laevis embryos by modi?ed growth”, Journal ofVlrology, 48(11):5891-5899. oligonucleotides possessing terminal cationic linkages.” Nucleic Pasternak, A. O., E. van den Born, et al. (2001). “Sequence require Acids Res., 28(10): 2153-7. ments for RNA strand transfer during nidovirus discontinuous de Vries, A. A. E, M. C. Horzinek, et al. (1997). “The Genome subgenomic RNA synthesis.” Embo J20(24):7220-8. Organization of the Nidovirales: Similarities and Differences Pasternak, A. O., E. van den Born, et al. (2003). “The Stability of the between Arteri-, Toro-, and Coronaviruses* 1.” Seminars in Virology, Duplex between Sense and Antisense Transcription-Regulating 8(1): 33-47. Sequences Is a Crucial Factor in Arterivirus Subgenomic mRNA Ding, D., S. M. Grayaznov, et al. (1996). “An Synthesis.” J Virol, 77(2): 1175-1 183. oligodeoxyribonucleotide N3‘.fwdarw.P5‘ phosphoramidate duplex Pasternak, A. O., W. J. Spaan, et al. (2004). “Regulation of relative forms anA-type helix in solution.”NucleicAcids Res., 24(2):354-60. abundance of arterivirus subgenomic mRNAs.” J Virol, Felgner, P. L., T. R. Gadek, et al. (1987). “Lipofection: a highly 78(15):8102-13. ef?cient, lipid-mediated DNA-transfection procedure.” Proc Natl Peiris, J. S., K. Y. Yuen, et al. (2003). “The severe acute respiratory Acad Sci USA, 84(21):7413-7. syndrome.” NEngl JMed., 349(25):2431-41. Gait, M. J., A. S. Jones, et al. (1974). “Synthetic-analogues of Rota, P. A., M. S. Oberste, et al. (2003). “Characterization of a novel polynucleotides XII. Synthesis of thymidine derivatives containing coronavirus associated with severe acute respiratory syndrome.” Sci an oxyacetamido- or an oxyformamido-linkage instead of a ence, 300(5624):1394-9. phosphodiester group.” J Chem Soc [Perkin 1] 0(14):1684-6. Savarinio et al., (2006). “Potential Therapies for Coronaviruses”, Gee, J. E., I. Robbins, et al. (1998). “Assessment of high-af?nity Expert. Opin. Ther., 1269-1288. hybridization, RNase H cleavage, and covalent linkage in translation Sawicki, S. G. and D. L. Sawicki (1998). “A new model for arrest by antisense oligonucleotides.” Antisense Nucleic Acid Drug coronavirus transcription.” Adv Exp Med Biol., 440:215-9. Dev., 8(2):103-11. Schiavone, N., et al., (2004). “Antisense oligonucleotide drug Guan,Y., B. J. Zheng, et al. (2003). “Isolation and Characterization of design”, Current Pharmaceutical Design, 10(7):769-784. Viruses Related to the SARS Coronavirus from Animals in Southern Stein, D., E. Foster, et al. (1997). “A speci?city comparison of four China.” Science, 302:276-278. antisense types: morpholino, 2‘-O-methyl RNA, DNA, and Hedges et al., (2004). J. Gen. Virol, 85(Part 2):379-390. phosphorothioate DNA.” Antisense Nucleic Acid Drug Dev., Homes et al., (2003). “The SARS Coronavirus: A Postgnomic Era”, 7(3): 15 1-7. Science, pp. 1377-1378. Summerton, J. and D. Weller (1997). “Morpholino antisense Lai, M. M. and D. Cavanagh (1997). “The molecular biology of oligomers: design, preparation, and properties.” Antisense Nucleic coronaviruses.”Adv Virus Res., 48: 1-100. Acid Drug Dev., 7(3):187-95. Lesnikowski, Z. J ., M. Jaworska, et al. (1990). “Octa(thymidine Thiel, V. et al., (Jun. 11, 1993), Genbank Accession No. AY291315, methanephosphonates) of partially de?ned stereochemistry: synthe “SARS Coronavirus Frankqu 1 Complete Genome”, [retrieved Mar. sis and effect of chirality at phosphorus on binding to 23, 2005]. pentadecadeoxyriboadenylic acid.” Nucleic Acids Res., 18(8):2109 Thiel, V., K. A. Ivanov, et al. (2003). “Mechanisms and enzymes 15. involved in SARS coronavirus genome expression.” J Gen Virol, Linkletter, B. A. and Bruice, T.C., “Solid-phase synthesis of posi 84(Pt 9): 2305-15. tively charged deoxynucleic guanidine (DNG) modi?ed Toulme, J. J., R. L. Tinevez, et al. (1996). “Targeting RNA structures oligonucleotides containing neutral urea linkages: Effect of charge by antisense oligonucleotides.” Biochimie, 78(7): 663-73. deletions on binding and ?delity.” Bioorg. Med Chem. 8(11):1893 Van Den Born, et al.
Load more

Recommended publications
  • Ribozyme-Mediated Inhibition of HIV 1 Suggests Nucleolar Trafficking of HIV-1 RNA
    Ribozyme-mediated inhibition of HIV 1 suggests nucleolar trafficking of HIV-1 RNA Alessandro Michienzi*, Laurence Cagnon*, Ingrid Bahner*, and John J. Rossi*†‡ *Department of Molecular Biology, Beckman Research Institute of the City of Hope, and †Graduate School of Biological Sciences, City of Hope, Duarte, CA 91010-3011 Communicated by Arthur Landy, Brown University, Providence, RI, May 30, 2000 (received for review April 22, 2000) The HIV regulatory proteins Tat and Rev have a nucleolar localiza- Ribozymes are RNAs with catalytic activity (28). The ham- tion property in human cells. However, no functional role has been merhead ribozyme is the simplest in terms of size and structure attributed to this localization. Recently it has been demonstrated and can readily be engineered to perform intermolecular cleav- that expression of Rev induces nucleolar relocalization of some age on targeted RNA molecules. These properties make this protein factors involved in Rev export. Because the function of Rev ribozyme a useful tool for inactivating gene expression and a is to bind HIV RNA and facilitate transport of singly spliced and potential therapeutic agent. Moreover, ribozymes can be very unspliced RNA to the cytoplasm, it is likely that the nucleolus plays effective inhibitors of gene expression when they are colocalized a critical role in HIV-1 RNA export. As a test for trafficking of HIV-1 with their target RNAs (29, 30). We have taken advantage of RNAs into the nucleolus, a hammerhead ribozyme that specifically ribozyme-mediated inactivation of targeted RNAs to investigate cleaves HIV-1 RNA was inserted into the body of the U16 small whether there is nucleolar trafficking of HIV RNA.
    [Show full text]
  • United States Patent (10) Patent No.: US 8,759,307 B2 Stein Et Al
    USOO87593 07B2 (12) United States Patent (10) Patent No.: US 8,759,307 B2 Stein et al. (45) Date of Patent: Jun. 24, 2014 (54) OLIGONUCLEOTIDE COMPOUND AND 2006/0287268 A1 12/2006 Iversen et al. ................... 514,44 METHOD FOR TREATING NIDOVIRUS 2007/0021362 A1 1/2007 Geller et al. .. 514,44 2007/0265214 A1 11/2007 Stein et al. .... ... 514/44 INFECTIONS 2009 OO88562 A1 4/2009 Weller et al. ................. 536,245 (75) Inventors: David A. Stein, Corvallis, OR (US); FOREIGN PATENT DOCUMENTS Richard K. Bestwick, Corvallis, OR (US); Patrick L. Iversen, Corvallis, OR WO WO2005/OOO234 A1 1, 2005 (US); Benjamin Neuman, Encinitas, CA WO WO2005/O13905 A1 2, 2005 (US); Michael Buchmeier, Encinitas, OTHER PUBLICATIONS CA (US); Dwight D. Weller, Corvallis, OR (US) Moulton etal Bioconjug Chem. Mar.-Apr. 2004:15(2): 290-9. Cellu lar uptake of antisense morpholino oligomers conjugated to arginine (73) Assignees: Sarepta Therapeutics, Inc., Corvallis, rich peptides.* OR (US); The Scripps Research Moulton etal AntisenseNucleic Acid Drug Dev. Feb. 2003: 13(1): 31 Institute, La Jolla, CA (US) 43. HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. (*) Notice: Subject to any disclaimer, the term of this Geller et al., Inhibition of Gene Expression in Escherichia coli by patent is extended or adjusted under 35 Antisense Phosphorodiamidate Morpholino Oligomers Antimicro U.S.C. 154(b) by 1101 days. bial Agents and Chemotherapy, Oct. 2003, p. 3233-3239, vol. 47, No. 1O.* Agrawal, S., S. H. Mayrand, et al. (1990). “Site-specific excision (21) Appl. No.: 12/109,856 from RNA by RNase H and mixed-phosphate-backbone oligodeoxynucleotides.” Proc Natl AcadSci USA, 87(4): 1401-5.
    [Show full text]
  • Inhibition of Hepatitis E Virus Replication by Peptide-Conjugated Morpholino Oligomers
    Inhibition of Hepatitis E Virus Replication by Peptide-Conjugated Morpholino Oligomers Nan, Y., Ma, Z., Kannan, H., Stein, D. A., Iversen, P. I., Meng, X. J., & Zhang, Y. J. (2015). Inhibition of hepatitis E virus replication by peptide-conjugated morpholino oligomers. Antiviral Research, 120, 134-139. doi:10.1016/j.antiviral.2015.06.006 10.1016/j.antiviral.2015.06.006 Elsevier Accepted Manuscript http://cdss.library.oregonstate.edu/sa-termsofuse *Manuscript Click here to view linked References 1 1 2 3 4 Inhibition of Hepatitis E Virus Infection by Peptide-Conjugated Morpholino Oligomers 5 6 7 8 a a a‡ c d 9 Yuchen Nan , Zexu Ma , Harilakshmi Kannan , David A. Stein , Patrick I. Iversen , Xiang-Jin 10 Menge, and Yan-Jin Zhanga,b* 11 12 13 14 15 16 17 aVA-MD College of Veterinary Medicine, and bMaryland Pathogen Research Institute, 18 19 20 University of Maryland, College Park, MD; 21 22 c d 23 Department of Biomedical Science, and Department of Environmental and Molecular 24 25 Toxicology, Oregon State University, Corvallis, OR; 26 27 e 28 Department of Biomedical Sciences and Pathobiology, College of Veterinary Medicine, 29 30 Virginia Polytechnic Institute and State University, Blacksburg, VA 31 32 33 34 35 36 37 38 39 ‡Present address: Merck & Co., Inc. West Point, PA. 40 41 42 43 * Address correspondence to: [email protected] 44 45 46 47 48 49 50 51 52 Total text words: 2952 53 54 55 56 57 58 59 60 61 62 63 64 65 1 2 2 3 4 ABSTRACT 5 6 7 Hepatitis E virus (HEV) infection is a cause of hepatitis in humans worldwide.
    [Show full text]
  • SARS-Cov-2 Subgenomic N (Sgn) Transcripts in Oro-Nasopharyngeal Swabs Correlate with the Highest Viral Load, As Evaluated by Five Different Molecular Methods
    diagnostics Article SARS-CoV-2 Subgenomic N (sgN) Transcripts in Oro-Nasopharyngeal Swabs Correlate with the Highest Viral Load, as Evaluated by Five Different Molecular Methods Massimo Zollo 1,2,3 , Veronica Ferrucci 1,2 , Barbara Izzo 1,2, Fabrizio Quarantelli 1, Carmela Di Domenico 1, Marika Comegna 1,2, Carmela Paolillo 4 , Felice Amato 1,2 , Roberto Siciliano 1, Giuseppe Castaldo 1,2,3 and Ettore Capoluongo 1,2,3,* 1 CEINGE, Biotecnologie Avanzate, 80131 Naples, Italy; [email protected] (M.Z.); [email protected] (V.F.); [email protected] (B.I.); [email protected] (F.Q.); [email protected] (C.D.D.); [email protected] (M.C.); [email protected] (F.A.); [email protected] (R.S.); [email protected] (G.C.) 2 Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università di Napoli Federico II, 80138 Naples, Italy 3 Department of Medicina di Laboratorio e Trasfusionale, AOU Federico II, 80138 Naples, Italy 4 Dipartimento di Clinica e Medicina Sperimentale, Università degli Studi di Foggia “Emanuele Altomare” Via Napoli, 121, 71122 Foggia FG, Italy; [email protected] * Correspondence: [email protected] Citation: Zollo, M.; Ferrucci, V.; Izzo, Abstract: Abstract: BackgroundThe COVID-19 pandemic has forced diagnostic laboratories to focus B.; Quarantelli, F.; Domenico, C.D.; on the early diagnostics of SARS-CoV-2. The positivity of a molecular test cannot respond to the Comegna, M.; Paolillo, C.; Amato, F.; question regarding the viral capability to replicate, spread, and give different clinical effects. Despite Siciliano, R.; Castaldo, G.; et al.
    [Show full text]
  • Expanded Subgenomic Mrna Transcriptome and Coding Capacity
    Expanded subgenomic mRNA transcriptome and coding PNAS PLUS capacity of a nidovirus Han Dia, Joseph C. Madden Jr.a, Esther K. Morantza, Hsin-Yao Tangb, Rachel L. Grahamc, Ralph S. Baricc,d, and Margo A. Brintona,1 aDepartment of Biology, Georgia State University, Atlanta, GA 30303; bProteomics and Metabolomics Facility, The Wistar Institute, Philadelphia, PA 19104; cDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599; and dDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 Edited by Paul Ahlquist, University of Wisconsin–Madison, Madison, WI, and approved August 28, 2017 (received for review April 24, 2017) Members of the order Nidovirales express their structural protein EAV particle assembly (12–14). The nucleocapsid (N) protein ORFs from a nested set of 3′ subgenomic mRNAs (sg mRNAs), and forms homodimers that interact with each other as well as with the for most of these ORFs, a single genomic transcription regulatory genomic RNA to form a “cage-like” nucleocapsid (15–17). The sequence (TRS) was identified. Nine TRSs were previously reported minor structural glycoproteins GP2, GP3, and GP4 form hetero- for the arterivirus Simian hemorrhagic fever virus (SHFV). In the trimers and function in cell-receptor recognition (18, 19). The present study, which was facilitated by next-generation sequencing, minor structural protein E forms oligomers and is thought to 96 SHFV body TRSs were identified that were functional in both function as an ion channel in the virion membrane during cell entry infected MA104 cells and macaque macrophages. The abundance (20).
    [Show full text]
  • The Alphaviruses: Gene Expression, Replication, and Evolution JAMES H
    MICROBIOLOGICAL REVIEWS, Sept. 1994, p. 491-562 Vol. 58, No. 3 0146-0749/94/$04.00+0 Copyright C) 1994, American Society for Microbiology The Alphaviruses: Gene Expression, Replication, and Evolution JAMES H. STRAUSS* AND ELLEN G. STRAUSS Division of Biology, Califomia Institute of Technology, Pasadena, Califomia 91125 INTRODUCTION ................................................... 492 The Cast of Characters ................................................... 492 Dispersal of Alphaviruses................................................... 494 Full-Length Clones of Alphaviruses................................................... 494 STRUCTURE OF ALPHAVIRUSES ................................................... 495 Structure of the Virion................................................... 495 Nucleocapsid................................................... 495 Virion envelope................................................... 496 Organization of the Alphavirus Genome................................................... 498 REPLICATION OF ALPHAVIRUSES................................................... 499 Overview of the Alphavirus Life Cycle................................................... 499 Structural Proteins ................................................... 499 Capsid protein................................................... 499 Synthesis of glycoproteins................................................... 500 Addition of carbohydrate and lipids ................................................... 502 Folding and transport of glycoproteins
    [Show full text]
  • Viral and Cellular Proteins Interacting with Transcription-Regulating Sequences
    REGULATION OF CORONAVIRUS TRANSCRIPTION: VIRAL AND CELLULAR PROTEINS INTERACTING WITH TRANSCRIPTION-REGULATING SEQUENCES Sonia Zúñiga, Isabel Sola, Jose L. Moreno, Sara Alonso, and Luis Enjuanes* 1. INTRODUCTION The last step in the current model of coronavirus transcription is a template switch during synthesis of the negative strand, to complete the minus sgRNA.1 It was shown that the free energy of duplex formation between leader transcription-regulating sequence (TRS-L) and the nascent negative-strand plays a crucial role in template switch and is the driving force of coronavirus transcription.2,3 This step requires overcoming an energy threshold. Coronavirus nucleoprotein (N) plays a structural role in virus assembly and has also been shown to be important in RNA synthesis.4 In addition, template switching, an obligatory step in CoV transcription, needs to overcome an energy threshold. Therefore, we asked whether RNA chaperones are involved in transcription and, most importantly, if N is an RNA chaperone. RNA chaperones are proteins that bind RNA with broad specificity and that rescue RNAs trapped in unproductive folding states.5-8 One of their main characteristics is that, once the RNA has been folded, they are no longer needed and, therefore, they can be removed without altering RNA conformation. There are three RNA chaperone activities easily evaluable in vitro: (i) enhancement of RNA ribozyme cleavage, (ii) rapid and accurate RNA-RNA annealing, and (iii) facilitation of RNA strand transfer and exchange. RNA chaperones decrease the activation energy required for a transition between two states, which is energetically favored. Template switch during coronavirus transcription could be interpreted as a transition between two states: in the first one, a duplex between the nascent minus RNA strand and the genomic positive RNA used as template is formed; in the second one, the nascent RNA strand is paired with the TRS of the leader.
    [Show full text]
  • Unconventional Viral Gene Expression Mechanisms As Therapeutic Targets
    Review Unconventional viral gene expression mechanisms as therapeutic targets https://doi.org/10.1038/s41586-021-03511-5 Jessica Sook Yuin Ho1,3, Zeyu Zhu1,3 & Ivan Marazzi1,2 ✉ Received: 8 June 2020 Accepted: 22 March 2021 Unlike the human genome that comprises mostly noncoding and regulatory sequences, Published online: 19 May 2021 viruses have evolved under the constraints of maintaining a small genome size while expanding the efciency of their coding and regulatory sequences. As a result, viruses Check for updates use strategies of transcription and translation in which one or more of the steps in the conventional gene–protein production line are altered. These alternative strategies of viral gene expression (also known as gene recoding) can be uniquely brought about by dedicated viral enzymes or by co-opting host factors (known as host dependencies). Targeting these unique enzymatic activities and host factors exposes vulnerabilities of a virus and provides a paradigm for the design of novel antiviral therapies. In this Review, we describe the types and mechanisms of unconventional gene and protein expression in viruses, and provide a perspective on how future basic mechanistic work could inform translational eforts that are aimed at viral eradication. Expression of a gene in the human genome is a multistep and heavily (for example, alternative splicing) or use unique strategies. Here we regulated process that resembles a production line. Protein-coding describe the diverse ways by which viral genomes give rise to genes and genes are transcribed almost exclusively by RNA polymerase II (RNAPII). proteins that deviate from the canonical framework of human genes, During transcription, quality-control checkpoints are implemented to restricting our analyses to eukaryotes and their viruses.
    [Show full text]
  • Coronavirus Transcription: a Perspective
    CTMI (2005) 287:31--55 Springer-Verlag 2005 Coronavirus Transcription: A Perspective S. G. Sawicki ()) · D. L. Sawicki Department of Microbiology, Medical College of Ohio, Toledo, OH 43614, USA [email protected] 1 Introduction ................................. 32 2 Discontinuous Transcription by Coronaviruses .............. 35 3 Kinetics of Plus- and Minus-Strand RNA Synthesis and Sensitivity to Translational Inhibition ................ 41 4 The Kinetics of Synthesis of the Subgenomic Minus Strands ...... 42 5 Subgenomic MHV RIs Exist in Infected Cells and Are Transcriptionally Active in mRNA 2–7 Synthesis ........ 43 6 Characterization of Coronavirus Native RI/TIs and Native RF/TFs ... 44 7 Turnover of MHV Replicative/Transcriptive Intermediates ....... 48 8 A Working Model ............................... 50 References....................................... 52 Abstract At the VIth International Symposium on Corona and Related Viruses held in QuØbec, Canada in 1994 we presented a new model for coronavirus transcription to explain how subgenome-length minus strands, which are used as templates for the synthesis of subgenomic mRNAs, might arise by a process involving discontinu- ous RNA synthesis. The old model explaining subgenomic mRNA synthesis, which was called leader-primed transcription, was based on erroneous evidence that only genome-length negative strands were present in replicative intermediates. To explain the discovery of subgenome-length minus strands, a related model, called the repli- con model, was proposed: The subgenomic mRNAs would be produced initially by leader-primed transcription and then replicated into minus-strand templates that would in turn be transcribed into subgenomic mRNAs. We review the experimental evidence that led us to formulate a third model proposing that the discontinuous event in coronavirus RNA synthesis occurs during minus strand synthesis.
    [Show full text]
  • Trans Regulation of Cap-Independent Translation by a Viral Subgenomic RNA Ruizhong Shen Iowa State University
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Digital Repository @ Iowa State University Plant Pathology and Microbiology Publications Plant Pathology and Microbiology 10-2006 trans Regulation of Cap-Independent Translation by a Viral Subgenomic RNA Ruizhong Shen Iowa State University Aurélie Mamisoa Rakotondrafara Iowa State University W. Allen Miller Iowa State University, [email protected] Follow this and additional works at: http://lib.dr.iastate.edu/plantpath_pubs Part of the Agricultural Science Commons, Molecular Biology Commons, and the Plant Pathology Commons The ompc lete bibliographic information for this item can be found at http://lib.dr.iastate.edu/ plantpath_pubs/31. For information on how to cite this item, please visit http://lib.dr.iastate.edu/ howtocite.html. This Article is brought to you for free and open access by the Plant Pathology and Microbiology at Iowa State University Digital Repository. It has been accepted for inclusion in Plant Pathology and Microbiology Publications by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. trans Regulation of Cap-Independent Translation by a Viral Subgenomic RNA Abstract Many positive-strand RNA viruses generate 3′-coterminal subgenomic mRNAs to allow translation of 5′-distal open reading frames. It is unclear how viral genomic and subgenomic mRNAs compete with each other for the cellular translation machinery. Translation of the uncapped Barley yellow dwarf virus genomic RNA (gRNA) and subgenomic RNAI (sgRNAI) is driven by the powerful cap-independent translation element (BTE) in their 3′ untranslated regions (UTRs). The TEB forms a kissing stem-loop interaction with the 5′ UTR to mediate translation initiation at the 5′ end.
    [Show full text]
  • Hepatitis Delta Virus RNA Replication
    Viruses 2009, 1, 818-831; doi:10.3390/v1030818 OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Review Hepatitis Delta Virus RNA Replication Chung-Hsin Tseng 1 and Michael M. C. Lai 1,2,3,* 1 Institute of Molecular Biology, Academia Sinica, Nankang, Taipei 115, Taiwan 2 Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA 3 National Cheng-Kung University, Tainan 701, Taiwan * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +886-2-27892365; Fax: +886-2-27826085. Received: 28 September 2009; in revised form: 3 November 2009 / Accepted: 3 November 2009 / Published: 6 November 2009 Abstract: Hepatitis delta virus (HDV) is a distant relative of plant viroids in the animal world. Similar to plant viroids, HDV replicates its circular RNA genome using a double rolling-circle mechanism. Nevertheless, the production of hepatitis delta antigen (HDAg), which is indispensible for HDV replication, is a unique feature distinct from plant viroids, which do not encode any protein. Here the HDV RNA replication cycle is reviewed, with emphasis on the function of HDAg in modulating RNA replication and the nature of the enzyme involved. Keywords: hepatitis delta virus; hepatitis delta antigen; RNA-dependent RNA synthesis; RNA polymerases; RNA replication 1. Introduction Hepatitis delta virus (HDV) was first discovered in 1977 among a group of patients infected with hepatitis B virus (HBV) [1]. Subsequent studies revealed that HDV is a defective virus, which requires a helper virus, HBV, to supply the hepatitis B surface antigen (HBsAg) for virion assembly and infectivity [2–4].
    [Show full text]
  • And Intramolecular Base Pairing for Translation Reinitiation on a Eukaryotic Bicistronic Mrna
    Downloaded from genesdev.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press The importance of inter- and intramolecular base pairing for translation reinitiation on a eukaryotic bicistronic mRNA Christine Luttermann and Gregor Meyers1 Institut fu¨ r Immunologie, Friedrich-Loeffler-Institut, D-72001 Tu¨ bingen, Germany Calicivirus structure proteins are expressed from a subgenomic mRNA with two overlapping cistrons. The first ORF of this RNA codes for the viral major capsid protein VP1, and the second for the minor capsid protein VP2. Translation of VP2 is mediated by a termination/reinitiation mechanism, which depends on an upstream sequence element of ;70 nucleotides denoted ‘‘termination upstream ribosomal binding site’’ (TURBS). Two short sequence motifs within the TURBS were found to be essential for reinitiation. By a whole set of single site mutations and reciprocal base exchanges we demonstrate here for the first time conclusive evidence for the necessity of mRNA/18S rRNA hybridization for translation reinitiation in an eukaryotic system. Moreover, we show that motif 2 exhibits intramolecular hybridization with a complementary region upstream of motif 1, thus forming a secondary structure that positions post-termination ribosomes in an optimal distance to the VP2 start codon. Analysis of the essential elements of the TURBS led to a better understanding of the requirements for translation termination/reinitiation in eukaryotes. [Keywords: Translation initiation; termination; reinitiation; TURBS; mammalian mRNA translation] Received September 23, 2008; revised version accepted December 22, 2008. Translation of proteins from mRNAs represents one of the protein synthesis after termination of translation of an basic processes in living organisms that allows us to upstream cistron (Kozak 1987, 2002; Meyers 2003; Gould differentiate them from nonliving replicating molecular and Easton 2005, 2007; Ryabova et al.
    [Show full text]